



Executive Committee

President

Dr. Alok Srivastava

Vice-President

Dr. Renu Saxena

Secretary

Dr. Shashikant Apte

Treasurer

Dr. Chandrakala
Shanmukhaiah

Members

Dr. Aby Abraham
Dr. Naresh Gupta
Dr. M Joseph John
Dr. Soniya Nityanand
Dr. Cecil Ross
Dr. Tulika Seth
Dr. Neeraj Sidharthan

Standing Committees

Chair, Directory Committee

Dr. M Joseph John

Co-Chairs, Education and Training Committee

Dr. Tulika Seth
Dr. Neeraj Sidharthan

Co-Chairs, Laboratory Committee

Dr. Renu Saxena
Dr. Sukesh C Nair

Co-Chairs, MSK Committee

Dr. Judy Ann David
Dr. Nittu Panjikaran

Chair, Nurses Committee

Dr. Sulochana (PhD)

IAHAD Office

Executive Advisor

Mr. Raghu Rajagopal

Operations Manager

Ms. Toshihira Aier

Program Executive

Ms. Manju Stephen

16.04.2025

To,

WHO Expert Committee on Selection and Use of Essential Medicines

World Health Organization

20, Avenue Appia

1211 Geneva 27

Switzerland

**Subject: IAHAD's letter of support for the World Federation of Haemophilia (WFH)
Applications for the Update of the WHO Essential Medicine List (2025).**

Dear Members of the WHO Expert Committee on Selection and Use of Essential Medicines,

Indian Association of Haemophilia and Allied Disorders, a non-profit organization of health care professionals, is very concerned about the impact of the current WHO Model Lists of Essential Medicines (EML). By inclusion of cryoprecipitate and exclusion of clotting factor concentrates for the management of haemophilia, this list can push back haemophilia care more than two decades. Through this letter, we would therefore like to record our own request and also support the three applications submitted by World Federation of Haemophilia (WFH) to the World Health Organization (WHO) for the update on this EML in 2025.

We truly believe that including newer and safer treatment products for Haemophilia and Von Willebrand Disease to the WHO EML and EMLc will greatly impact the quality of life of people with Haemophilia and other bleeding disorders around the globe. At the same time, we would like to raise our concern on inclusion of pathogen-reduced and non-pathogen-reduced cryoprecipitate as core medicines on the Model Lists of Essential Medicines in 2023, while the virally safe, plasma derived CFCs remain on the complementary medicines list. These are completely incongruous with current practices and guidelines.

In this regard, we express our support for the WFH's below three proposals:

- **A.12 Emicizumab – haemophilia A** <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/25th-expert-committee-on-selection-and-use-of-essential-medicines/a.12-emicizumab-haemophilia-a>
- **A.23 Recombinant coagulations factors- haemophilia** <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/25th-expert-committee-on-selection-and-use-of-essential-medicines/a.23-recombinant-coagulation-factors-haemophilia>
- **C.1 Changes to listings of cryoprecipitate, pathogen-reduced cryoprecipitate, and plasma-derived clotting factor concentrates** <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/25th-expert-committee-on-selection-and-use-of-essential-medicines/c.1-changes-to-listings-of-cryoprecipitate-pathogen-reduced-cryoprecipitate-and-plasma-derived-clotting-factor-concentrates>



It is very important that the WHO EML include recommendations which recognize the advances in therapies based on the products currently available with high safety and efficacy way beyond cryoprecipitate. Most importantly, cryoprecipitate is just not suitable for prophylaxis which is the only way to management haemophilia as per current guidelines.

We very much hope the concerned WHO committee will consider these requests and our support for the proposals from WFH regarding this matter which can enhance the health outcomes and adopt best practices in the treatment of Haemophilia.

Sincerely,

Dr. Alok Srivastava
President, IAHAD

Dr. Renu Saxena
Vice President, IAHAD

Dr. Shashikant Apte
Secretary, IAHAD

Dr. Chandrakala S
Treasurer, IAHAD

On behalf of Executive Committee, IAHAD